REQUEST A DEMO
Total
USD $0.00
Search more companies

Qilian International Holding Group Ltd. (China)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Qilian International Holding Group Ltd. Profile Updated: March 16, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

The Company engages in the research, development, and production of active pharmaceutical ingredients, traditional Chinese medicine derivatives, and other by-products in China.
The Company has three operating segments: Oxytetracycline Licorice products and TCMD, Fertilizer, Heparin products and Sausage casing.
The Company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil s chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth.
2019 The Company s a Cayman Islands exempted company incorporated on February 7, 2019 as a holding company to develop business opportunities in the People's Republic of China. The Company s a wholly-owned subsidiary of Qilian International formed in accordance with the laws and regulations of Hong Kong on January 30, 2019.
2021 The Company is ordinary Shares commenced trading on the Nasdaq Global Market under the symbol “QLI.” in January 12, 2021.

Headquarters
Jiuquan Economic And Technological Development Zone, Gansu Province
Jiuquan; Gansu; Postal Code: 735000

Contact Details: Purchase the Qilian International Holding Group Ltd. report to view the information.

Website: http://www.qlsyy.net

Basic Information
Total Employees:
Purchase the Qilian International Holding Group Ltd. report to view the information.
Outstanding Shares:
Purchase the Qilian International Holding Group Ltd. report to view the information.
Financial Auditors:
Purchase the Qilian International Holding Group Ltd. report to view the information.
Incorporation Date:
2019
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chief Financial Officer
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Inside Director
Purchase this report to view the information.
Outside Director
Ownership Details
Purchase this report to view the information.
33.57%
Purchase this report to view the information.
19.95%
Purchase this report to view the information.
18.79%
Purchase this report to view the information.
5.14%
Purchase this report to view the information.
Subsidiaries
Qilian International (Hong Kong) Holdings Limited (Hong Kong SAR, China)
Company Performance
Financial values in the chart are available after Qilian International Holding Group Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency USD. Absolute financial data is included in the purchased report.
Net sales revenue
-56.92%
Total operating revenue
-56.92%
Operating profit (EBIT)
N/A
EBITDA
N/A
Net Profit (Loss) for the Period
-25.06%
Total assets
-22.39%
Total equity
-17.93%
Operating Profit Margin (ROS)
N/A
Net Profit Margin
1.11%
Return on Equity (ROE)
-0.07%
Quick Ratio
4.3%
Cash Ratio
1.22%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?